Press release summary
Bora Biologics and Protect Animal Health have entered a long-term collaboration covering the development and manufacturing of antibody-based veterinary products. Protect expects to advance at least three programs through the partnership, including two monoclonal antibodies and one bispecific antibody. The agreement marks Boraโs first animal-health collaboration.
Bora will support the programs from cell-line and process development through analytical development, scale-up and biologics manufacturing. The work will use Boraโs CHO-K1 cell-line platform and its U.S. and Taiwan manufacturing network. The companies said the programs are intended for U.S. and international veterinary markets, although they did not identify specific disease targets, development timelines or regulatory milestones.
Why it matters for laboratories
Antibody programs depend on consistent transitions from early cell-line work to analytical characterization and larger-scale production. Keeping those stages within an integrated development network can reduce technology-transfer gaps and help establish methods that remain suitable as production expands. The collaboration also reflects growing use of complex biologics in veterinary medicine, including bispecific formats that require additional analytical and manufacturing controls. Laboratory and development teams should watch for future disclosures on product targets, assay strategies and program progression.
Original source: Bora Biologicsโ Oct. 4, 2026, announcement.






Leave a Reply